CAPItello-280 trial aims to confirm findings from ProCAID trial
At the recent ACSO-GU symposium, the design and study endpoints from the CAPItello-280 trial were presented. The trial-in-progress aims to confirm the findings made in the ProCAID study, investigating the effects and safety of adding capivasertib to docetaxel chemotherapy in patients with metastatic castration-resistant prostate cancer (CRPC).
Få tillgång
Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.
- Få tillgång
- Om du redan har en profil: Logga in